ReForm’s technology platform enables biologics to be administered subcutaneously.
For patients, this offers the promise of taking their medicines by a simple injection at home or at a physician’s office instead of receiving a time-consuming, inconvenient, and possibly painful infusion in a clinic or hospital setting.
Formulations of biologic medicines commonly face viscosity and stability problems. ReForm leverages a mechanistic understanding of protein-protein and protein-solvent interactions to identify and design excipients that improve viscosity and stability. Founded by David Soane, a prolific entrepreneur in the advanced materials, polymer chemistry, and surface science fields, many of ReForm’s excipients are based on well-established chemical structures with familiar toxicology profiles and prior pharmaceutical uses and are protected by a comprehensive patenting strategy.